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Abstract
Based on the directive from President George W. Bush to prepare the nation better for a possible smallpox attack,
Florida enacted Operation Vaccinate Florida- Stage I (OVF I). Between February 10, 2003, and March 31, 2003,
Florida vaccinated 4,434 individuals against smallpox. During this period a smallpox vaccine surveillance study
was conducted in 18 counties in North Central Florida. The study was conducted via journal log, which participants
completed daily by recording all symptoms, vaccination site stage development, and demographic information. The
study included 350 vaccinees from Alachua, Baker, Bradford, Clay, Columbia, Dixie, Duval, Hamilton, Gilchrist,
Lafayette, Levy, Flagler, Marion, Nassau, Putnam, Union, St. Johns, and Suwannee Counties. All symptoms
experienced by study participants were normal and expected. Itching was experienced by 99.3% of the participants
and site stage development was typical for the vaccinia virus. Naïve vaccinees had a longer mean vaccine site
duration compared to non-naïve vaccinees.
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Introduction
After September 11, 2001 the United States
government declared an increased need for
bioterrorism awareness and training. A perceived
threat of an intentional release of the smallpox virus
was identified. In response to this apparent threat,
President George W. Bush initiated a nationwide
smallpox vaccination campaign. This campaign
targeted persons that have the highest probability of
coming into contact with the virus and include:
healthcare workers, public health and hospital
personnel and emergency response teams. Each
participant in Florida chose voluntarily to receive the
vaccine and was excluded if any contradictions (i.e.
pregnancy, suppressed immune system, skin
conditions, etc) existed.
There are risks and side effects associated
with the vaccine (Sibley, 2002). Some of these are
considered non-serious reactions and are expected to
occur. These expected non-serious reactions include:
low grade fever, itching at the vaccination site,
muscle aches, chills, nausea, fatigue, and joint pains
(Frey, Couch, Tacket, et al, 2002; Sibley, 2002;
Smallpox Fact Sheet, 2003). Other more severe
reactions can occur and range from serious to life
threatening. In previous vaccination sessions
approximately 1,000 of every 1 million naïve
vaccinees incurred a serious reaction that required
medical treatment. These reactions included:
erythema multiforme, inadvertent inoculation, and
generalized vaccinia. It is estimated that 1 or 2 out of
1 million vaccinees could die from the vaccine
(Smallpox Fact Sheet, 2003).When the smallpox
vaccine is properly administered as a preexposure
prophylactic, it is 95%-98% effective in preventing
smallpox (Sibley, 2002). The vaccine effectiveness
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decreases when administered as postexposure
prophylaxis and vaccine effectiveness also decreases
the longer the duration after exposure (Sibley, 2002).
Florida began its vaccination campaign
(OFVI) in February 2003. A coalition of eighteen
counties in North Central Florida agreed to have all
smallpox vaccination participants complete a daily
journal that would record the following facts:
demographics, site stage duration, mild and severe
reactions, loss of work, and medical care sought. The
duration of the surveillance project was from
February 10, 2003 to May 1, 2003 and included 350
participants.
Methods
An 18-county consortium in North Central
Florida was developed for this project and included:
Alachua, Baker, Bradford, Clay, Columbia, Dixie,
Duval, Hamilton, Gilchrist, Lafayette, Levy, Flagler,
Marion, Nassau, Putnam, Union, St. Johns, and
Suwannee counties. Each of the 18 volunteer
counties offered the smallpox journal to all
individuals receiving the smallpox vaccine during
OVF1. Each county also designated an individual
(nurse, doctor) to monitor the vaccinee recipients’
health status and aid in journal completion.
The vaccine journal was developed based on
previously documented reactions of the Dry Vax®
smallpox vaccine manufactured by Wyeth
Laboratories Inc., Marietta, Pennsylvania. The
journal was developed to obtain information about
vaccinees demographics, medical reactions to the
vaccine, daily behavior modifications, and monitor
stage development of the vaccine site. The smallpox
vaccine journal was developed and approved by key
stakeholders, including the Florida Department of
43
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Health and directors of participating county health
departments. Due to the time constraints of the
vaccination program the vaccine journal was unable
to be pre-tested.
The journal was designed as a daily log to be
completed by the individual vaccinee, site change
nurse, or via telephone. The journal was completed
daily until the scab fell off (point when no longer
infectious to others). Each day the vaccinee would
document all symptoms that occurred during the
previous 24-hrs. Participants had the ability to record
the occurrence of up to 37 symptoms each day (Table
1). Additional information was asked the day the
scab fell off in “yes/no” format. Only symptoms
experienced by over 10% of the vaccinees were
included in the analysis.
Participation in the study was limited to
smallpox vaccine recipients living in the eighteen
county consortium, who received the smallpox
vaccine during OVFI, and who returned their journal
log. Journals were made available at the time of
vaccination and were either given directly to the
vaccinee or kept in the vaccinees’ chart to be
completed during the daily dressing check. A total of
350 journals were returned from all eighteen
counties. Participation in the study was voluntary.
The study was conducted throughout the
duration of OVF1, from February 10, 2003 to May 1,
2003. The data collected in the journals were
collected and analyzed using Epi Info 2002 and SPSS
version 12.0. The response rate, frequencies,
measures of central tendency and dispersion, and chisquare tests for significance were calculated. An
alpha level of 0.05 was used to determine
significance. An index was used to better ascertain
overall health effects on study participants. Overall
health effects, characterized as ‘symptom-days’, the
sum of all symptoms experienced in N number of
days a vaccinee is followed, was calculated for each
participant in the study group. Each symptom
experienced was treated as an independent
symptomatic day. This method accounts for
differences in follow up time by treating each
independent symptom frequency as 1 symptom-day
(Figures 1 and 2).
Results
The sample population consisted of 350
vaccinees out of a possible 472, yielding a response
rate of 74.2% for the consortium and represented
9.4% of Florida’s vaccinees in OVF I. Of the
participants, 305 (89.4%) were white, 232 (66.5%)
were female, and 253 (72.3%) ranged between 40-59
years of age (Figure 3).
Of the 350 participants, 315 (90.0%) had
successful takes, as assessed and documented by a
Florida Public Health Review, 2006; 3:43-50
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nurse or physician. Of the 35 individuals who had
unsuccessful takes, 13 (37.1%) chose to be
revaccinated.
Of the 350 participants, 5 (6.8%) reported
either missing work or school and 4 (5.5%) reported
missing recreational activities. Six (2.0%) of the
vaccinees sought medical attention during the post
vaccination period. No vaccinee reported a personal
contact (e.g. household member, sexual partner, or
work contact) with lesions of undetermined etiology.
The mean vaccination length, the mean
length of duration between vaccination and scab
drop, among the study participants (N=350) was
24.35 days and the range was 50-8 days. The mean
vaccination length for naïve vaccinees (n=15) was
27.5 days and ranged from a minimum of 12 to a
maximum of 50 days. The mean vaccination length
among previous vaccinees (n=101) was 21.2 days
and ranged from a minimum of 8 days to a maximum
of 40 days. There was a statistically significant
difference in mean vaccination length between
primary and secondary vaccinees (p= 0.001), with a
difference of 6.3 days between means.
The presence of a papule, the first stage of
the vaccination site, occurred days 1-6; the mode
occurred on day 2 with 52 (55.8%) vaccinees
reporting papules (Figure 4.1). The vesicle, the
second stage of the vaccine site, occurred from day 27; the mode occurred on day 5 with 62 (53.2%)
vaccinees reporting vesicles (Figure 4.2). The
pustule, the third stage of the site development, was
reported as occurring from days 3-19; the mode
occurred on day 6 among the 64 (84.4%) vaccinees
reporting pustules (Figure 4.3). The scab, the final
stage of site development, was recorded as occurring
from days 1-35; the mode occurred on day 14 with 58
(89.7%) vaccinees reporting scabs (Figure 4.4).
The study group symptoms included:
itching at vaccine site (99.3%), sore arm at vaccine
site (37.3%), swollen lymph nodes (24.9%),
headache (24.9%), redness >2/3inch at vaccine site
(16.6%), fatigue (16.0%), allergic rash from tape
dressing (14.2%), muscle aches (13%), and size of
vaccine site >1/2inch (10.1%). Vaccinees reported
the majority of symptoms between days 4-8 (Figure
5). There was not a significant difference in the
number of symptoms reported by the naïve vaccinees
when compared to the number of symptoms reported
by pre-vaccinees. The study participants reported a
total of 564 symptom-days during the study period.
Discussion
Past studies report that 21% of naïve
individuals sought medical attention (Smallpox Fact
Sheet, 2003). This current study followed both naïve
and prevaccinated individuals. A low percentage
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(6.8%) of the study participants missed work or
school due to symptoms and only 2% sought medical
attention. Reasons for the lower number of vaccinees
seeking medical attention may include: better
screening methods were used to eliminate individuals
at a high risk for adverse reactions, primary vaccinees
were discouraged from participating, and daily site
checks by a medial professional may have reduced
the number of patients that otherwise would have
sought outside medical advice.
Participant’s
vaccination
sites
were
monitored daily for site stage development. The site
stage developments observed in this study was
similar to vaccination studies performed before
smallpox eradication. In previous studies, papules
formed on days 2-3, vesicles formed on day 3-5,
pustules formed on day 5-7, and scabs formed on day
10-12 (Sibley, 2002). In this post smallpox
eradication study, the majority of the papules formed
on day 1-3, the majority of vesicles formed on days
2-7, the majority of the pustules formed on days 5-10
and the majority of the scabs formed on days 9-22.
Naïve vaccinees experienced longer mean
site duration than secondary vaccinees. The longer
mean site duration among naïve participants is
consistent
to
what
would
be
expected
immuniologically.
No unexpected reactions or symptoms were
seen in the participants during this study. Allergic
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rashes from the vaccine site dressings occurred in
14.2% of the patients. Unlike previous vaccination
studies the dressing sites were required to be covered
with extreme diligence. This diligence in covering
the vaccine site and disposing of soiled material
properly demonstrated its effectiveness, as no
secondary transmissions were identified during the
study period.
The investigators had a unique opportunity
to observe how a sample of the civilian population in
2003 would respond to the smallpox vaccine
compared to previous populations. The daily log
provided a means for monitoring the health status of
vaccinees and provided insight into the site stage
progression that has not been documented previously
for 21st century population.
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Table 1. List of Symptoms Presented to Vaccinees on Journal Log

Headache
Chills
Fever
Muscle Aches
Joint Paint
Loss of Appetite
Fatigue
Swollen/tender lymph nodes
Sore arm where vaccine given
Swelling at site of vaccine >2/3inch
Redness at site of vaccine >2/3inch
Size of pustule >1/2inch
Problems sleeping
Allergic rash from tape/dressing
Itching at site of vaccine
Sores anywhere else on body
Abdominal pain
Other
No symptoms

Rash anywhere on body
Difficulty staying awake
Difficulty breathing
Hoarseness
Wheezing
Hives
Paleness
Weakness
Fast heartbeat
Dizziness
Eye infection
Inadvertent inoculation
Generalized Vaccinia
Erythema multiforme
Eczema vaccinaum
Secondary infection at vaccine site
Postvaccinal encephalitis
Death

Figure 1. Total Number of Symptom-Days Recorded for Prevaccinated Smallpox Vaccinees in an Eighteen
County Region of North Central Florida, 2003.
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Figure 2. Total Number of Symptom-Days Recorded for Primary Smallpox Vaccinees Among an Eighteen
County Region of North Central Florida, 2003.
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Figure 3. Age range for Smallpox Vaccine Recipients in an Eighteen County Region of North Central Florida,
2003
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Figure 4. Smallpox Vaccine Site Development in an Eighteen County Region of North Central Florida, 2003
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Figure 4.1
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Figure 4.2
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Figure 4.4

Figure 5. ‘No Symptoms’ For All Vaccinees by Day Number for Eighteen County Region in North Central
Florida, 2003
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